The purpose of this trial is to determine the effectiveness of early, intensive antihyperintensive treatment using intravenous nicardipine in people with hypertension and intracerebral hemorrhage (ICH). Nicardipine is an antihypertensive medication.
An estimated 37,000 to 52,400 people in the United States have ICH every year. ICH is a form of stroke that has poor outcome and is difficult to treat. It is associated with the highest mortality rate of all strokes. Hematoma expansion has been identified as the most common cause of neurological deterioration in people with ICH. Early evidence suggests that acute hypertension (HTN), or elevated blood pressure, may make some individuals more susceptible to hematoma expansion. Treating HTN may prevent hematoma expansion, however, the effect of aggressive HTN treatment has not been determined.
This 5-year, international, multi-center trial—which will enroll 1280 individuals— is the natural extension of numerous case series, a subsequent pilot trial (ATACH-I), and a preliminary randomized controlled trial (INTERACT-I). The purpose is to evaluate the efficacy and safety of using nicardipine to lower blood pressure in people who have acute HTN associated with ICH.
*Note: Patients with SBP < 180mmHg should be monitored for 4.5 hours from symptom onset as their SBP may rise to eligible levels before the eligibility window closes.
Contact: Adnan I Qureshi, MD; telephone: 612-625-1969; email: email@example.com;
Last Reviewed December 17, 2012